A new approach to dose escalation in non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 1, 2001, Pages 23-33

  Mehta, Minesh ^a,c   Scrimger, Rufus ^a   Mackie, Rock ^a,b   Paliwal, Bhudatt ^a   Chappell, Rick ^b   Fowler, Jack ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NONE   (United States)

Author keywords

Acceleration; Bayesian; Dose escalation; Dose per fraction; Fraction size; Helical tomotherapy; Intensity modulation; Lung cancer; Non small cell lung cancer; Phase I trial

Indexed keywords

ARTICLE; BAYES THEOREM; BREATH HOLDING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; ESOPHAGUS INJURY; HELICAL TOMOTHERAPY; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; STANDARD; SURVIVAL TIME; TECHNIQUE; TECHNOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; HUMANS; LUNG NEOPLASMS; RADIATION PNEUMONITIS; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 0035169875     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01374-2     Document Type: Article

References (56)

1. Cancer statistics, 1999
2. Combined modality treatment for stage III non-small cell lung cancer
3. Improved survival in Stage III non-small cell lung cancer; Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
4. Radiotherapy alone vs. combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer; First analysis of a randomized trial in 353 patients
5. Localized adenocarcinoma of the lung; A retrospective study of 186 non-metastatic patients from the French Federation of Cancer Institutes-the Radiotherapy Cooperative Group
6. Evaluation of adjuvant postoperative radiotherapy for lung cancer
7. Impact of irradiation technique and tumor extension on tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung
8. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer; A randomized multicenter trial
9. Local control in medically inoperable lung cancer; An analysis of importance in outcome and factors determining the probability of tumor eradication
10. Local irradiation alone for stage I lung cancer; Could we omit the elective regional nodal irradiation?
11. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer; The Duke experience
12. Impact of tumor control on survival in carcinoma of the lung treated with irradiation
13. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer (RTOG, ECOG & SWOG)
14. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers; Results of the EORTC 22851 randomized trial
15. Estimation of tumor control probability parameters from 3-D dose distributions of non-small cell lung cancer patients
16. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas; First report of RTOG 90-03
17. Tomotherapy
18. Radiation pneumonitis as a function of mean lung dose; An analysis of pooled data of 540 patients
19. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung; Analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trials
20. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the respiratory/digestive tracts. New evidence for accelerated proliferation from RTOG Protocol 83-13
21. Non small cell lung tumors repopulate rapidly during radiation therapy
22. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy
23. Altered fractionation trials in head and neck cancer
24. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes
25. The importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma is dependent on tumor differentiation
26. Accelerated fractionation; What is the price for speeding?
27. The hazard of accelerated tumor clonogen repopulation during radiotherapy
28. The linear-quadratic formula and progress in fractionated radiotherapy
29. A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity
30. Time factors in larynx tumor radiotherapy; Lag times and intertumor heterogeneity in clinical datasets from four centers
31. Isoeffect models and fractionated radiation therapy
32. The delay before onset of accelerated tumor cell repopulation during radiotherapy; A direct-maximum likelihood analysis of a collection of worldwide tumor-control data
33. The influence of radiotherapy treatment time on the control of laryngeal cancer; A direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor
34. The clinical significance of ratios of radiobiological parameters
35. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations
36. Accelerated repopulation during radiotherapy; Quantitative evidence for delayed onset
37. Radiation pneumonitis; A new approach to the derivation of time-dose factors
38. Radiation pneumonitis; Experience following a large single dose of radiation
39. Idiopathic interstitial pneumonia following bone marrow transplantation; The relationship with total body irradiation
40. Repair in mouse lung for up to 20 fractions of X-rays or neutrons
41. Acute radiation-induced pulmonary damage; A clinical study on the response to fractionated radiation therapy
42. Radiation-induced lung damage; Dose-time-fractionation considerations
43. Time-dose factors in radiotherapy; A review of the human data
44. Evaluation of isoeffect formulae for predicting radiation-induced lung damage
45. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease; The role of fractionation
46. Injury to the lung from cancer therapy; Clinical syndromes, measurable endpoints, and potential scoring systems
47. Continual reassessment method; A practical design for Phase I clinical trials in cancer
48. The continual reassessment method in cancer phase I clinical trials; A simulation study
49. Practical modifications of the continual reassessment method for phase I cancer clinical trials
50. Repair half-times estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer